Lupus & antiphospholipid syndrome
Serum pentraxin 3 in systemic lupus erythematosus: A potential indicator of cutaneous disease activity
Authors' conclusion
Our results reinforce the important role of Pentraxin3 in SLE patients with skin manifestations, and it may be considered an interesting biomarker for the pattern and extent of cutaneous involvement in SLE.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (with and without skin manifestations) and healthy subjects34 SLE patients · 30 healthy subjects
- Participants
- 17 / 17 / 30
- Comparison
- SLE patients vs healthy controls; SLE with vs without skin manifestations
- SLE WITH SKIN MANIFESTATIONSn = 17
- SLE WITHOUT SKIN MANIFESTATIONSn = 17
- Controlsn = 30reference
- Outcome
- Serum PTX3 level (ELISA)
Main finding
As reported in the abstract
Serum PTX3 level
- Higher serum pentraxin3 (PTX3) level in SLE patients vs controls
- p < 0.001
- Higher PTX3 level in patients with vs without skin manifestations
- p < 0.001
Observational data: associations, not effects.
Further findings
SLEDAI-2K scores, SLE with vs without skin manifestations
- Higher SLEDAI-2K scores in patients with skin manifestations
- P = 0.015
PTX3 level by skin manifestation
- Higher PTX3 with malar rash
- P < 0.001
- Higher PTX3 with mucosal ulcers
- P < 0.001
- Higher PTX3 with alopecia
- P < 0.001
- Higher PTX3 with purpuric eruption
- P = 0.002
Correlation of PTX3 with CLASI scores
- PTX3 level positively correlated with CLASI scores
- P < 0.001
Original publication
Serum pentraxin 3 in systemic lupus erythematosus: A potential indicator of cutaneous disease activity. Lupus. Published 14 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →